Caplin Point Laboratories Management Guidance Tracker

8 forward-looking guidance items tracked across 2 quarters.

Revenue

Q3 FY26High double-digit revenue growth for Caplin Steriles USATracked

Expect high double-digit revenue growth in the next years for Caplin Steriles and Caplin USA.

Q4 FY26CSL overall growth 25-30% in FY27Tracked

Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches.

Q4 FY26Own-label revenue target ~₹200 crore in FY27Tracked

Aim to double own-label revenue from ~₹100 crore to ~₹200 crore in the next fiscal year.

Growth

Q3 FY2612-13 ophthalmic and prefilled syringe products for approval by end of next yearTracked

Expect to complete at least 12-13 products in ophthalmic and prefilled syringe range within next 12 months, coming up for approval by end of next year.

Q3 FY26First DMF filing from Vizag API plant by end of this yearTracked

Targeting first DMF filing from Vizag API plant by end of this year, with 2-3 more APIs scaled up monthly.

Margins

Q3 FY26PAT margin to remain in 26-29% rangeActive

Management expects PAT margin to stay in the 26-29% path, with potential for improvement as new initiatives fire.

Capex

Q4 FY26Capex of ~₹500 crore over next 18-24 monthsTracked

Remaining capex of about ₹500 crore to be spent on injectable plant phase 3, oral solids/derma facility, and oncology API plant.

Expansion

Q4 FY2617 injectable lines in 2-3 yearsTracked

Company plans to have 17 injectable lines for US and regulated markets, with most machines imported from Germany and Italy.